Loading…

Loading grant details…

Completed SBIR-STTR RPGS NIH (US)

Wearable Graphene Respiratory Sensor for Early Detection and Monitoring of Asthma

$4.32M USD

Funder NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Recipient Organization Aquillius Corporation
Country United States
Start Date Sep 20, 2024
End Date Sep 30, 2025
Duration 375 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10922558
Grant Description

Project Summary / Abstract Asthma is a chronic, non-communicable disease that affects 300 million children and adults worldwide. In the United States alone, asthma burdens 26 million citizens. With the rise of global temperatures, climate change is adding to the complexity of asthma occurrences. Changes in environmental conditions can lead to negative

downstream effects such as prolonged pollen seasons that can elevate aeroallergens. Increase in aeroallergens are concerning due to its association to allergen-induced asthma. Asthma is a debilitating disease that has no cure, and the severity of the disease varies person to person. Diagnosis and monitoring in children is challenging

due to an inability to follow technical instructions to perform lung functioning tests such as spirometry and their inability to communicate symptoms. To alleviate difficulties associated with diagnosis and monitoring of asthma treatments in children, Aquillius Corporation proposes to develop a respiratory sensor capable of real-time

continuous monitoring and measuring of pulmonary functions. Utilizing graphene nanotechnology, this innovative device will be cost-effective, robust, and suitable for all ages. Our approach seeks to improve patient monitoring, treatment, and diagnosis of asthma through development of innovative respiratory sensor. To reach this goal,

Aquillius will (i) Optimization of respiratory sensor’s function by utilizing a manikin lung simulator for normal and asthma conditions; and (ii) Demonstrate the ability of GNS respiratory sensor to capture pulmonary function data in real time. Upon the successful completion of Phase I feasibility studies, Phase II will focus on development

and refinement of the device by incorporating human test subjects with asthma. The end-user interface and software will also be further developed. Overall, the commercialization of the respiratory sensor will greatly improve patient care by measuring a patient’s lung function in real-time, thus helping with both accurate diagnosis

and personalized asthma treatments.

All Grantees

Aquillius Corporation

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant